InspireMD Inc. buy stratec
Start price
10.01.18
/
50%
€5,512.5
Target price
10.01.19
€13,388
Performance (%)
-98.00%
End price
10.01.19
€110.25
Summary
This prediction ended on 10.01.19 with a price of €110.25. Massive losses of -98.00% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| InspireMD Inc. | -1.020% | -1.020% | -57.826% | -25.385% |
| iShares Core DAX® | 0.224% | 1.487% | 3.575% | 50.284% |
| iShares Nasdaq 100 | 6.047% | 16.188% | 39.144% | 107.459% |
| iShares Nikkei 225® | 5.724% | 11.690% | 50.962% | 76.350% |
| iShares S&P 500 | 2.172% | 8.056% | 25.618% | 72.625% |
Comments by stratec for this prediction
In the thread InspireMD Inc. diskutieren
InspireMD expects Q4 2017 sales of ~$833K (+159%)
The company says the CGuard* stent is designed to prevent embolization (blocking a blood vessel) by
trapping potential emboli against the arterial wall while maintaining excellent blood flow.
* Das CGuardTM Embolic Prevention System (EPS) wurde entwickelt, um eine peri-prozedurale und späte Embolisation zu verhindern, indem mögliche Emboli gegen die Arterienwand abgefangen werden, während gleichzeitig eine ausgezeichnete Perfusion zu der äußeren Halsschlagader und den
Nebengefäßen aufrechterhalten wird.
(Laufzeit überschritten)